Dolutegravir based two-drug regimen in clinical routine

被引：0
|
作者：
Hoeller, Hannes [1 ]
Jaeger, Hans [1 ]
Jonsson-Oldenbuettel, Celia [1 ]
Heldwein, Silke [1 ]
Schabaz, Farhad [1 ]
von Krosigk, Ariane [1 ]
Wiese, Carmen [1 ]
Wolf, Eva [2 ]
Noe, Sebastian [1 ]
机构：
[1] MVZ Munchen Goethepl, Munich, Germany
[2] MUC Res GmbH, Munich, Germany
来源：
INFECTION | 2021年 / 49卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
016
引用
收藏
页码：S11 / S11
页数：1
相关论文
共 50 条
  • [41] Lipid changes in real-world studies with the two-drug regimen dolutegravir and lamivudine (DTG+3TC) in people with HIV-1: a systematic literature review
    Letang, E.
    Lo, J.
    Milinkovic, A.
    Maggiolo, F.
    di Giambenedetto, S.
    Mussini, C.
    Yoruk, I. Ungan
    Henegar, C.
    Priest, J.
    Young, B.
    Kabra, M.
    Jones, B.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2022, 25 : 154 - 156
  • [42] Patient-reported outcomes after switching to a two-drug regimen of fixed-dose combination dolutegravir/lamivudine: 48-week results from the SALSA study
    Kumar, Princy
    Clarke, Amanda E.
    Jonsson-Oldenbuttel, Celia
    Garcia Deltoro, Miguel
    Di Giambenedetto, Simona
    Brites, Carlos
    Hocqueloux, Laurent
    Lu, Po-Liang
    Oyee, James
    Oglesby, Alan
    Priest, Julie
    Blair, Elizabeth
    Wynne, Brian
    Gordon, Lori A.
    Latang, Emilio
    van Wyk, Jean
    Evitt, Lee A.
    HIV MEDICINE, 2022, 23 : 55 - 56
  • [43] Performance of dolutegravir-based two-drug regimens (DTG-2DR) in a large real-world cohort of people with HIV
    Bowman, Conor
    Ambrose, Alissa
    Simoes, Pedro
    Florman, Katia
    Kanitkar, Tanmay
    Katiyar, Abhishek
    Hunter, Alan
    Hart, Jennifer
    Barber, Tristan
    HIV MEDICINE, 2022, 23 : 24 - 24
  • [44] Performance of dolutegravir-based two-drug regimens (DTG-2DR) in a large real-world cohort of people with HIV
    Bowman, C.
    Ambrose, A.
    Simoes, P.
    Florman, K.
    Kanitkar, T.
    Katiyar, A.
    Hunter, A.
    Hart, J.
    Barber, T.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2022, 25 : 94 - 95
  • [45] Two-drug regimens for HIV treatment
    Gibas, Kevin M.
    Kelly, Sean G.
    Arribas, Jose R.
    Cahn, Pedro
    Orkin, Chloe
    Daar, Eric S.
    Sax, Paul E.
    Taiwo, Babafemi O.
    LANCET HIV, 2022, 9 (12): : E868 - E883
  • [46] Two-drug antiretroviral regimens for HIV
    Thornhill, John P.
    Cromarty, Ben
    Gaddie, Jessica
    Mushunje, Shiellah
    Ferrand, Rashida A.
    BMJ-BRITISH MEDICAL JOURNAL, 2023, 382
  • [47] Patient-reported outcomes after switching to a two-drug regimen of dolutegravir plus rilpivirine: Week 100 results from the SWORD-1 and SWORD-2 studies
    Oglesby, A.
    Angelis, K.
    Punekar, Y.
    Lopes, S.
    Antela, A.
    Aboud, M.
    Blair, E.
    Kahl, L.
    Gartland, M.
    Wynne, B.
    Murray, M.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2018, 21
  • [48] Predicting two-drug antiretroviral regimen efficacy by genotypic susceptibility score: results from a cohort study
    Rossetti, B.
    Redi, D.
    Ciccullo, A.
    Lombardi, F.
    Paolucci, S.
    Bellazzai, L.
    Di Biagio, A.
    Penco, G.
    Lepore, L.
    Monno, L.
    Rusconi, S.
    Carli, T.
    Modica, S.
    Gagliardini, R.
    Zazzi, M.
    De Luca, A.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2018, 21
  • [49] High persistence of dolutegravir-containing 2-drug regimens in routine clinical care
    Noe, S.
    Jonsson-Oldenbuettel, C.
    Heldwein, S.
    Wiese, C.
    von Krosigk, A.
    Schabaz, F.
    Jaeger, H.
    Wolf, E.
    HIV MEDICINE, 2019, 20 : 73 - 73
  • [50] Residual viremia in HIV-infected patients who continue a two-drug or switch to a three-drug integrase strand transfer inhibitor based regimen
    Gianotti, Nicola
    Galli, Laura
    Poli, Andrea
    Torre, Liviana Della
    Vinci, Concetta
    Carini, Elisabetta
    Galli, Andrea
    Nozza, Silvia
    Spagnuolo, Vincenzo
    Muccini, Camilla
    Lazzarin, Adriano
    Castagna, Antonella
    AIDS, 2021, 35 (09) : 1513 - 1516
12345